Human Technology Decides to Absorb Wholly-Owned Subsidiary Human Agos in a No-Stock-Issuance Merger, No Shareholder Dilution
Human Technology decided to absorb its wholly-owned subsidiary Human Agos on September 1, 2026.
The merger is conducted without issuing new shares, so there is no dilution for existing shareholders.
The purpose is to increase operational efficiency, improve financial structure, and diversify into new businesses such as anti-drone solutions.
Human Agos had negative equity of 894 million KRW as of end-2025, with a net loss of 4.42 billion KRW, indicating a complete capital impairment.
As a small-scale merger, shareholder approval is replaced by board approval, and appraisal rights are not granted.
Human Technology has provided a 3 billion KRW fixed deposit as collateral for a guarantee from Kookmin Bank and has a 4 billion KRW short-term loan to Human Agos.
[AI Summary]Human Technology's absorption of its subsidiary is neutral to shareholder value due to no dilution, but the subsidiary's poor financial condition with capital impairment and recurring losses may burden the combined entity. While operational efficiency and business diversification are expected in the short term, the direct absorption of the loss-making subsidiary's debts and operating losses is an investment risk to consider.
KOSDAQ Filing Information
[Correction of Description] Report On Major Matters (Decision On Company Merger)